This Adipose Banking Digest gathers the 2026 developments so far that touch adipose tissue banking, each with its date and a primary source. It covers a court order, FDA guidance and warning letters, a standards revision, state law, and pipeline figures, plus what none of it changes for banked tissue.
TLDR The 2026 Adipose Banking Digest covers an August 28 permanent injunction treating adipose-derived SVF products as drugs, a February draft guidance and a May final guidance from FDA, several warning letters to companies marketing unapproved cell and exosome products, and an AATB standards revision effective January 31, 2027. None of these items approves an adipose product. Banking adipose tissue does not guarantee eligibility for, access to, or benefit from any future therapy.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No item in this digest is an FDA approval of any adipose-derived product. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
News about stem cells arrives in pieces: a court order in one place, an FDA guidance in another, a standards bulletin behind a members page. It is hard to tell which pieces matter.
This digest puts the dated items in one place. Save My Fat has published more than two hundred educational articles on adipose tissue banking, the FDA framework, state stem cell laws, and the adipose-derived cell trial pipeline since February 2026. A measurable share of this site’s visitors now arrive from AI assistants rather than from a classic search results page. Each item below carries a date, a source, and what it does and does not mean.
For the science, see our year in review. This page sticks to dated legal, regulatory, and standards items.
What did the court decide on August 28, 2026?
A federal court permanently barred two companies from distributing adipose-derived SVF products outside FDA pathways. On August 28, 2026, the Central District of California entered a permanent injunction against California Stem Cell Treatment Center, Inc. and Cell Surgical Network Corporation, along with one individual defendant. The order declares the covered products, which contain SVF or cells derived from adipose tissue, to be drugs.
The order bars the defendants from receiving, manufacturing, processing, labeling, or distributing those products unless they are covered by an approved new drug application, an IND, or a Biologics License Application. It requires an IND submission for each product within 60 days.
What did FDA guidance change in 2026?
FDA issued two relevant guidance documents in 2026, and neither changes the Part 1271 rules that apply to banked tissue. The first is a February 2026 plausible mechanism guidance about individualized therapies for specific genetic conditions. It discusses genome editing and RNA-based therapies and contains no reference to cell therapy, autologous products, adipose tissue, stem cells, or SVF. Comments closed April 27, 2026, and it remains a draft.
The second is a May 2026 final CMC guidance on manufacturing flexibility for cellular and gene therapy products headed to a Biologics License Application. It does not apply to clinic products. Our CMC flexibility guidance explainer covers it. None of FDA’s six 2026 cellular and gene therapy guidances concerns Part 1271.
Which FDA warning letters went out in 2026?
FDA sent several warning letters in 2026 to companies marketing unapproved cell and exosome products. Three CBER letters from its database are summarized below, and none of them concerned SVF or adipose products.
The first went to Dynamic Stem Cell Therapy on February 11, 2026, about an umbilical cord derived product and exosome products. The second went to Blue Horizon International, LLC on May 26, 2026, about cord blood derived and Wharton’s jelly exosome products. The third went to R3 Medical Companies on August 14, 2026, about umbilical cord, cord blood, and exosome products. Background on how these letters work sits in our guide to FDA warning letters.
On May 11, 2026, FDA also posted a consumer warning about unapproved products made from human cells or tissues. It cites adverse event reports, including patient deaths.
Adipose Banking Digest table: every dated item at a glance
The table lists each dated item in this digest, including one 2025 state law. The source type column shows whether an item is a court record, an FDA document, a private standard, or a state law, and the last column gives its meaning for banked tissue.
| Date | Item | Source type | What it means for banking |
|---|---|---|---|
| May 13, 2025 | Montana SB 535 effective | State law | Licenses centers, not tissue banks |
| February 11, 2026 | Warning letter, Dynamic Stem Cell Therapy | FDA warning letter | Birth tissue and exosomes, not adipose |
| February 2026 | Plausible mechanism draft guidance | FDA draft guidance | No mention of cell therapy or adipose |
| May 2026 | CMC flexibilities final guidance | FDA final guidance | Applies to BLA products only |
| May 11, 2026 | Consumer warning on unapproved cell products | FDA safety page | Reinforces that unapproved products carry risk |
| May 26, 2026 | Warning letter, Blue Horizon International | FDA warning letter | Birth tissue and exosomes, not adipose |
| July 27, 2026 | AATB Bulletin 26-1 | Private standards body | Revised standards take effect January 31, 2027 |
| August 14, 2026 | Warning letter, R3 Medical Companies | FDA warning letter | Birth tissue and exosomes, not adipose |
| August 28, 2026 | Permanent injunction, C.D. Cal. | Federal court order | Adipose-derived SVF products treated as drugs |
Read down the last column: nothing in 2026 approved, cleared, or created a new route to use banked adipose tissue.
What changed in tissue banking standards?
AATB released a third revision to its Standards for Tissue Banking, 15th edition, and it takes effect January 31, 2027. AATB Bulletin 26-1, dated July 27, 2026, announced the revision. One change replaces the term “ambient” with a defined temperature range. The bulletin does not publish the range.
AATB accreditation is a private, non governmental program, separate from FDA registration. If you are comparing banks, ask each one directly whether it holds AATB accreditation and how it plans to meet the revised standards.
What is the newest state law item?
The newest state law item in this digest is Montana SB 535, effective May 13, 2025, and no 2026 state enactment is included here. SB 535 created a license for “experimental treatment centers” in Montana, with a $10,000 application fee and a $5,000 annual renewal. It does not approve or license any product, and its text does not mention tissue banks, stem cells, or adipose tissue. Our state law update tracks the wider state picture.
Where does the approval pipeline stand?
The latest published RMAT figures run only through fiscal year 2025, and no 2026 totals are posted. FDA’s cumulative RMAT page reports 388 requests received since December 13, 2016, with 193 granted. In fiscal year 2025, FDA received 91 requests and granted 50.
On the approval side, FDA approved Ryoncil on December 18, 2024 for steroid refractory acute graft versus host disease in pediatric patients 2 months and older. It is an allogeneic, bone marrow derived MSC therapy, not adipose and not autologous. Our Ryoncil update explains the distinction.
What does none of it change for banked tissue?
None of these items approves a use for banked adipose tissue or creates a new pathway for it. The court order targets specific companies, the guidances address development programs rather than Part 1271, the warning letters summarized here concern birth tissue and exosome marketers, and the AATB revision is not yet in effect.
Banked adipose tissue remains stored tissue, not a therapy. Any future use depends on FDA regulatory status, physician guidance, and whether an approved or investigational pathway exists at that time.
What to watch in the rest of 2026
Only one item on this list has a known future date: the AATB revision takes effect January 31, 2027. The February plausible mechanism guidance is still a draft, and no date for a final version appears in this digest’s sources, so its next step is unknown.
Frequently Asked Questions
Did the August 2026 injunction make adipose tissue banking illegal?
The order is directed at the named defendants and the SVF and adipose-derived products they prepare, which it treats as drugs. Ask a licensed provider or an attorney how any ruling applies to you.
Did FDA approve any adipose-derived product in 2026?
No item in this digest is an approval of an adipose-derived product.
Does the new AATB revision affect tissue already stored?
The bulletin does not say how the revision applies to stored tissue. Ask your bank how it plans to comply by January 31, 2027.
Key Takeaways
This Adipose Banking Digest found no 2026 item that approves or opens a route for using banked adipose tissue. A federal court treated one group’s adipose-derived SVF products as drugs on August 28. FDA’s two guidances address genetic therapies and BLA manufacturing, not Part 1271. FDA sent several warning letters in 2026 to companies marketing unapproved cell and exosome products. The AATB standards revision takes effect January 31, 2027. RMAT totals stop at fiscal year 2025. Talk with a licensed provider before acting on any of it.
Save My Fat connects patients and providers with a U.S.-based tissue bank. It is not a tissue bank, a laboratory, a medical practice, or a treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, California, Georgia, and Tennessee governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Readers tracking these rules and weighing adipose tissue banking for potential future use can check current pricing or send questions through the contact page.
Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Please consult your own licensed healthcare provider before making any decisions about treatment or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: FDA adipose tissue regulation.
